<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">hpDK5PnVzxz6ZQkF5vgNF5r</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2023001000201</article-id>
      <article-id pub-id-type="other">00201</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20230666</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Velocidade de Onda de Pulso: Chegou a Hora de Reduzir o Ponto de Corte?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6025-9821</contrib-id>
          <name>
            <surname>Santos-Veloso</surname>
            <given-names>Marcelo Ant&#244;nio Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade Federal de Pernambuco</institution>
        <institution content-type="orgdiv1">Programa de P&#243;s-Gradua&#231;&#227;o em Inova&#231;&#227;o Terap&#234;utica</institution>
        <addr-line>
          <named-content content-type="city">Recife</named-content>
          <named-content content-type="state">PE</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal de Pernambuco &#8211; Programa de P&#243;s-Gradua&#231;&#227;o em Inova&#231;&#227;o Terap&#234;utica, Recife, PE &#8211; Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Hospital Alfa</institution>
        <addr-line>
          <named-content content-type="city">Recife</named-content>
          <named-content content-type="state">PE</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital Alfa - Servi&#231;o de Cl&#237;nica M&#233;dica, Recife, PE &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Marcelo Ant&#244;nio Oliveira Santos-Veloso &#8226; Universidade Federal de Pernambuco &#8211; Programa de P&#243;s-Gradua&#231;&#227;o em Inova&#231;&#227;o Terap&#234;utica &#8211; Av. Prof. Moraes Rego, 1235. CEP 50670-901, Cidade Universit&#225;ria, Recife, PE &#8211; Brasil E-mail: <email>marcelosantos.med@gmail.com</email> </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>30</day>
        <month>10</month>
        <year>2023</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2023</year>
      </pub-date>
      <volume>120</volume>
      <issue>10</issue>
      <elocation-id>e20230666</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>09</month>
          <year>2023</year>
        </date>
        <date date-type="rev-recd">
          <day>04</day>
          <month>10</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Hipertens&#227;o</kwd>
        <kwd>T&#233;cnicas de Diagn&#243;stico Cardiovascular</kwd>
        <kwd>An&#225;lise de Onda de Pulso</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>Hipertens&#227;o arterial sist&#234;mica (HAS) &#233; a doen&#231;a cr&#244;nica n&#227;o transmiss&#237;vel mais prevalente no Brasil, comumente agravada por dist&#250;rbios metab&#243;licos, tais como diabetes mellitus, dislipidemia e obesidade.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Devido ao seu curso silencioso, a pesquisa de les&#245;es subcl&#237;nicas em est&#225;gios iniciais &#233; essencial para instituir medidas de preven&#231;&#227;o de complica&#231;&#245;es cardiovasculares. A identifica&#231;&#227;o de risco com marcadores sens&#237;veis possibilita terap&#234;utica precoce, reduzindo a morbimortalidade associada &#224;s doen&#231;as cardiovasculares.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
    <p>A velocidade de onda de pulso (VOP) &#233; considerada o padr&#227;o-ouro para identifica&#231;&#227;o de arteriosclerose. H&#225; rela&#231;&#227;o de dose-resposta entre o aumento da VOP e ocorr&#234;ncia de desfechos cardiovasculares maiores, como s&#237;ndrome coronariana aguda, s&#237;ndromes cerebrovasculares e morte.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
    <p>Apesar da import&#226;ncia da VOP, n&#227;o h&#225; consenso sobre o melhor ponto de corte na identifica&#231;&#227;o precoce de les&#227;o de &#243;rg&#227;o alvo (LOA) em pacientes com HAS. O ponto de corte ideal sofre influ&#234;ncia de diversos fatores como m&#233;todo de aferi&#231;&#227;o, etnia, idade, comorbidades e grau de LOA instalado.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> As diretrizes europeia, japonesa e coreana recomendam um ponto de corte de 10 m/s para VOP car&#243;tido-femoral,<sup><xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref></sup> enquanto a chinesa adota o valor de 12 m/s.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
    <p>No artigo desta edi&#231;&#227;o, Inuzuka et al.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> propuseram-se identificar o melhor ponto de corte de VOP car&#243;tido-femoral para identifica&#231;&#227;o de LOA em pacientes HAS na popula&#231;&#227;o brasileira. As LOA analisadas foram espessura m&#233;dio-intimal carot&#237;dea (EMIC) ou placa ateromatosa na ultrassonografia de car&#243;tidas e hipertrofia ventricular esquerda (HVE) ao ecocardiograma.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
    <p>Os autores sugerem um ponto de corte de 8,2 m/s, por&#233;m com modestos valores de &#225;rea sob curva (ASC) ROC: 0,678 para EMIC; 0,717 para HVE e 0,649 para placa carot&#237;dea. N&#227;o foi calculada a curva ROC para o modelo geral, ou seja, no qual a presen&#231;a de qualquer das tr&#234;s LOAs fosse considerada.</p>
    <p>A ASC &#233; um dado amplamente utilizado em estudos diagn&#243;stico e representa a acur&#225;cia do m&#233;todo: quanto maior (pr&#243;ximo a 1,0), melhor a capacidade discriminat&#243;ria entre paciente com e sem LOA. Os valores da ASC podem ser classificados como ruim, moderado, bom ou excelente. Embora n&#227;o haja consenso, a maioria dos autores classifica como excelente ASC com valores 0,90-1,00; bom entre 0,75-0,90; moderado entre 0,70-0,75 e ruim abaixo de 0,70.<sup><xref ref-type="bibr" rid="B10">10</xref></sup></p>
    <p>Uma importante limita&#231;&#227;o do estudo &#233; a aus&#234;ncia do c&#225;lculo do intervalo de confian&#231;a (IC) 95%. Devido a imprevisibilidade inerente &#224; estat&#237;stica, o valor real de qualquer vari&#225;vel deve variar 95% das vezes entre dois extremos que chamamos IC. Por exemplo, para uma ASC de 0,70 e IC 95% entre 0,6-0,8 o valor real da ASC n&#227;o &#233; 0,70, mas sim um valor que pode estar entre 0,60 e 0,80. E, a diferen&#231;a entre o valor superior e inferior desse intervalo &#233; determinado pelo tamanho da amostra: quanto maior a amostra, menor o intervalo e mais precisa a aferi&#231;&#227;o.</p>
    <p>Devido &#224; pequena amostra, &#233; poss&#237;vel que o IC 95% das ASC apresentadas contenha o valor de 0,5 (ex: 0,6 [0,5-0,7]), o que significaria que na verdade n&#227;o h&#225; poder discriminat&#243;rio do m&#233;todo aplicado.</p>
    <p>Recentemente, uma metan&#225;lise com dados individuais de 5836 pacientes dos estudos IDCARS e MONICA avaliou o ponto de corte ideal de VOP car&#243;tido-femoral para predizer mortalidade geral e eventos cardiovasculares fatais e n&#227;o fatais. O ponto de corte de 9 m/s foi o melhor para predi&#231;&#227;o dos desfechos, com ASC 0.691 (0.647&#8211;0.735) e 0.691 (0.647&#8211;0.735), respectivamente, para indiv&#237;duos do IDCARS e MONICA.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
    <p>A despeito das limita&#231;&#245;es, os resultados de Inuzuka et al.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> retratam dados nacionais e convergem com achados mais robustos para indicar a necessidade de redu&#231;&#227;o dos pontos de corte tradicionalmente recomendados pelas diretrizes internacionais.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Oliveira IM, Araujo TA, Roediger MA, Zanetta DMT, Andrade FB. Factors Associated with Undiagnosed Hypertension Among Elderly Adults in Brazil - ELSI-Brazil. Cien Saude Colet. 2022;27(5):2001-10. doi: 10.1590/1413-81232022275.12512021.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Roediger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Zanetta</surname>
              <given-names>DMT</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>FB</given-names>
            </name>
          </person-group>
          <article-title>Factors Associated with Undiagnosed Hypertension Among Elderly Adults in Brazil - ELSI-Brazil</article-title>
          <source>Cien Saude Colet</source>
          <year>2022</year>
          <volume>27</volume>
          <issue>5</issue>
          <fpage>2001</fpage>
          <lpage>2010</lpage>
          <pub-id pub-id-type="doi">10.1590/1413-81232022275.12512021</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Barroso WKS, Rodrigues CIS, Bortolotto LA, Mota-Gomes MA, Brand&#227;o AA, Feitosa ADM, et al. Brazilian Guidelines of Hypertension - 2020. Arq Bras Cardiol. 2021;116(3):516-658. doi: 10.36660/abc.20201238.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barroso</surname>
              <given-names>WKS</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>CIS</given-names>
            </name>
            <name>
              <surname>Bortolotto</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Mota-Gomes</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Brand&#227;o</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Feitosa</surname>
              <given-names>ADM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Brazilian Guidelines of Hypertension - 2020</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2021</year>
          <volume>116</volume>
          <issue>3</issue>
          <fpage>516</fpage>
          <lpage>658</lpage>
          <pub-id pub-id-type="doi">10.36660/abc.20201238</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Valencia-Hern&#225;ndez CA, Lindbohm JV, Shipley MJ, Wilkinson IB, McEniery CM, Ahmadi-Abhari S, et al. Aortic Pulse Wave Velocity as Adjunct Risk Marker for Assessing Cardiovascular Disease Risk: Prospective Study. Hypertension. 2022;79(4):836-43. doi: 10.1161/HYPERTENSIONAHA.121.17589.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valencia-Hern&#225;ndez</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Lindbohm</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>McEniery</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Ahmadi-Abhari</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Aortic Pulse Wave Velocity as Adjunct Risk Marker for Assessing Cardiovascular Disease Risk: Prospective Study</article-title>
          <source>Hypertension</source>
          <year>2022</year>
          <volume>79</volume>
          <issue>4</issue>
          <fpage>836</fpage>
          <lpage>843</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.17589</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. An DW, Hansen TW, Aparicio LS, Chori B, Huang QF, Wei FF, et al. Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity: An Individual-Participant Meta-Analysis. Hypertension. 2023;80(9):1949-59. doi: 10.1161/HYPERTENSIONAHA.123.21318.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>An</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Aparicio</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Chori</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>QF</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>FF</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity: An Individual-Participant Meta-Analysis</article-title>
          <source>Hypertension</source>
          <year>2023</year>
          <volume>80</volume>
          <issue>9</issue>
          <fpage>1949</fpage>
          <lpage>1959</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.123.21318</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Mancia G, Fagard R, Narkiewicz K, Red&#243;n J, Zanchetti A, B&#246;hm M, et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mancia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fagard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Narkiewicz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Red&#243;n</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zanchetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>B&#246;hm</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title>
          <source>J Hypertens</source>
          <year>2013</year>
          <volume>31</volume>
          <issue>7</issue>
          <fpage>1281</fpage>
          <lpage>1357</lpage>
          <pub-id pub-id-type="doi">10.1097/01.hjh.0000431740.32696.cc</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Kim HC, Ihm SH, Kim GH, Kim JH, Kim KI, Lee HY, et al. 2018 Korean Society of Hypertension Guidelines for the Management of Hypertension: Part I-Epidemiology of Hypertension. Clin Hypertens. 2019;25:16. doi: 10.1186/s40885-019-0121-0.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Ihm</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HY</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2018 Korean Society of Hypertension Guidelines for the Management of Hypertension: Part I-Epidemiology of Hypertension</article-title>
          <source>Clin Hypertens</source>
          <year>2019</year>
          <volume>25</volume>
          <size units="pages">16</size>
          <pub-id pub-id-type="doi">10.1186/s40885-019-0121-0</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235-481. doi: 10.1038/s41440-019-0284-9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umemura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Asayama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dohi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirooka</surname>
              <given-names>Y</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)</article-title>
          <source>Hypertens Res</source>
          <year>2019</year>
          <volume>42</volume>
          <issue>9</issue>
          <fpage>1235</fpage>
          <lpage>1481</lpage>
          <pub-id pub-id-type="doi">10.1038/s41440-019-0284-9</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A Report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16(3):182-241. doi: 10.11909/j.issn.1671-5411.2019.03.014.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Joint Committee for Guideline Revision</collab>
          </person-group>
          <article-title>2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A Report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension</article-title>
          <source>J Geriatr Cardiol</source>
          <year>2019</year>
          <volume>16</volume>
          <issue>3</issue>
          <fpage>182</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.11909/j.issn.1671-5411.2019.03.014</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Inuzuka S, Vitorino PVO, Barroso AS, Magalh&#227;es FG, Sousa AC, Alves Filho RPP, et al. Pulse Wave Velocity of 8.2 m/s as a Threshold Associated with Cardiovascular Target Organ Damage. Arq Bras Cardiol. 2023; 120(10):e20220934. DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20220934">https://doi.org/10.36660/abc.20220934</ext-link>.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inuzuka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vitorino</surname>
              <given-names>PVO</given-names>
            </name>
            <name>
              <surname>Barroso</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Magalh&#227;es</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>RPP</given-names>
              <suffix>Filho</suffix>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Pulse Wave Velocity of 8.2 m/s as a Threshold Associated with Cardiovascular Target Organ Damage</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2023</year>
          <volume>120</volume>
          <issue>10</issue>
          <elocation-id>e20220934</elocation-id>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20220934">https://doi.org/10.36660/abc.20220934</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. de Hond AAH, Steyerberg EW, van Calster B. Interpreting Area Under the Receiver Operating Characteristic Curve. Lancet Digit Health. 2022;4(12):e853-e855. doi: 10.1016/S2589-7500(22)00188-1.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Hond</surname>
              <given-names>AAH</given-names>
            </name>
            <name>
              <surname>Steyerberg</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>van Calster</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Interpreting Area Under the Receiver Operating Characteristic Curve</article-title>
          <source>Lancet Digit Health</source>
          <year>2022</year>
          <volume>4</volume>
          <issue>12</issue>
          <fpage>e853</fpage>
          <lpage>e855</lpage>
          <pub-id pub-id-type="doi">10.1016/S2589-7500(22)00188-1</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>
          <italic>Minieditorial referente ao artigo: Velocidade de Onda de Pulso de 8,2m/s como Limiar Associado &#224; Les&#227;o de &#211;rg&#227;o Alvo Cardiovascular</italic>
        </p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pulse Wave Velocity: Is It Time to Reduce the Cutoff Point?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6025-9821</contrib-id>
          <name>
            <surname>Santos-Veloso</surname>
            <given-names>Marcelo Ant&#244;nio Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Universidade Federal de Pernambuco &#8211; Programa de P&#243;s-Gradua&#231;&#227;o em Inova&#231;&#227;o Terap&#234;utica, Recife, PE &#8211; Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital Alfa - Servi&#231;o de Cl&#237;nica M&#233;dica, Recife, PE &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001"> Mailing Address: Marcelo Ant&#244;nio Oliveira Santos-Veloso &#8226; Universidade Federal de Pernambuco &#8211; Programa de P&#243;s-Gradua&#231;&#227;o em Inova&#231;&#227;o Terap&#234;utica &#8211; Av. Prof. Moraes Rego, 1235. Postal Code 50670-901, Cidade Universit&#225;ria, Recife, PE &#8211; Brazil E-mail: marcelosantos.med@gmail.com </corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Hypertension</kwd>
        <kwd>Diagnostic Techniques, Cardiovascular</kwd>
        <kwd>Pulse Wave Analysis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>Systemic arterial hypertension (SAH) is Brazil&#8217;s most prevalent chronic non-communicable disease, commonly aggravated by metabolic disorders, such as diabetes mellitus, dyslipidemia, and obesity.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Due to its silent course, research into subclinical injuries in the early stages is essential to establish measures to prevent cardiovascular complications. Risk identification with sensitive markers enables early therapy, reducing morbidity and mortality associated with cardiovascular diseases.<sup><xref ref-type="bibr" rid="B2">2</xref></sup></p>
      <p>Pulse wave velocity (PWV) is the gold standard for identifying arteriosclerosis. There is a dose-response relationship between increased PWV and the occurrence of major cardiovascular outcomes, such as acute coronary syndrome, cerebrovascular syndromes, and death.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>Despite the importance of PWV, there is no consensus on the best cutoff point for the early identification of target organ damage (TOD) in patients with SAH. The ideal cutoff point is influenced by several factors such as measurement method, ethnicity, age, comorbidities, and degree of TOD established.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> European, Japanese, and Korean guidelines recommend a cutoff point of 10 m/s for carotid-femoral PWV.<sup><xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref></sup> At the same time, the Chinese guideline adopts the value of 12 m/s.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
      <p>In the article on this issue, Inuzuka et al.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> proposed to identify the best carotid-femoral PWV cutoff point for identifying TOD in SAH patients in the Brazilian population. The TOD analyzed were carotid intima-media thickness (CIMT) or atheromatous plaque on carotid ultrasound and left ventricular hypertrophy (LVH) on echocardiography.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
      <p>The authors suggest a cutoff point of 8.2 m/s but with a modest area under the curve (AUC) ROC values: 0.678 for CIMT, 0.717 for LVH, and 0.649 for carotid plaque. The ROC curve was not calculated for the general model, in which the presence of any of the three TODs was considered.</p>
      <p>The AUC is data widely used in diagnostic studies and represents the accuracy of the method: the higher it is (close to 1.0), the better the discriminatory capacity between patients with and without TOD. AUC values can be classified as poor, moderate, good, or excellent. Although there is no consensus, most authors classify AUC as excellent with values 0.90-1.00, good between 0.75-0.90, moderate between 0.70-0.75, and poor below 0.70.<sup><xref ref-type="bibr" rid="B10">10</xref></sup></p>
      <p>An important limitation of the study is the lack of calculation of the 95% confidence interval (CI). Due to the inherent unpredictability of statistics, the real value of any variable must vary 95% of the time between two extremes that we call CI. For example, for an AUC of 0.70 and a 95% CI between 0.6-0.8, the real AUC value is not 0.70 but rather a value that can be between 0.60 and 0.80. Furthermore, the difference between this range&#8217;s upper and lower value is determined by the sample size: the larger the sample, the smaller the range and the more precise the measurement.</p>
      <p>Due to the small sample, it is possible that the 95% CI of the AUC presented contains a value of 0.5 (ex: 0.6 [0.5-0.7]), which would mean that there is actually no discriminatory power of the method applied.</p>
      <p>Recently, a meta-analysis with individual data from 5836 patients from the IDCARS and MONICA studies evaluated the ideal cutoff point for carotid-femoral PWV to predict overall mortality and fatal and non-fatal cardiovascular events. The cutoff point of 9 m/s was the best for predicting outcomes, with AUC 0.691 (0.647&#8211;0.735) and 0.691 (0.647&#8211;0.735), respectively, for individuals from IDCARS and MONICA.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
      <p>Despite the limitations, the results of Inuzuka et al.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> portray national data and converge with more robust findings to indicate the need to reduce the cutoff points traditionally recommended by international guidelines.<sup><xref ref-type="bibr" rid="B9">9</xref></sup></p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>
            <italic>Short editorial related to the article: Pulse Wave Velocity of 8.2 m/s as a Threshold Associated with Cardiovascular Target Organ Damage</italic>
          </p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
